Avicanna unveils large-scale MyMedi.ca medical cannabis study
Avicanna released information on a new study through MyMedi.ca which will look into the use of medical cannabis for various health ailments such as pain, anxiety, epilepsy, sleep, and depression.
Image | © adobestock.com/tadamichi
In a recent press release (1), Avicanna recently announced a new study through MyMedi.ca, a medical cannabis care platform, which will be orchestrated by Hance Clarke, MD, FRCPC, PhD, President of The Canadian Pain Society and Canadian Consortium for the Investigation of Cannabinoids.
The focus of this study is to observe the medicinal use of cannabis and how it affects patients suffering from epilepsy, anxiety, depression, pain, and sleep. A total of 1,000 patient all over the US will be enrolled to take part and contribute to the research data. Researchers will gather the data through validated questionnaires which will help them comprehend how different medical cannabis products aid in the treatment of these health ailments, as well as “the change in use of concomitant medication over a 24-week duration,” (1).
“I am pleased that Avicanna has stepped up to support this important work. We must continue to gather data and better understand what effects these cannabis products are having on Canadian patients that are approaching cannabis for therapeutic benefit,” Dr. Clarke commented (1).
“MyMedi.ca medical cannabis care platform was established with a number of goals that included, access to medical cannabis, providing patient support and education, and facilitating research on cannabinoid medicines,” Dr. Karolina Urban, Executive Vice President Medical Affairs explained (1). Dr. Urban added that, “We are excited to support the Study and hope that the results of this study will provide data, evidence, and increase our understanding of the potential impacts of medical cannabis across a range of conditions that may facilitate the incorporation of medical cannabis into standard of care.”
According to the press release (1), the study was first started by “Medical Cannabis by Shoppers” and was part of the focus Avicanna shares to advance medical research and patient care platform. MyMedi.ca will offer support for patients, infrastructure, and education for participating health care practitioners (HCPs). Patients participating in the study will be able to utilize the platform’s products. For example, Avicanna’s RHO Phyto formulary and additional products sourced from select licensed producers who are assisting in supporting the study (1).
If you are interested in learning more, please visit www.mcrwe.com, or reach out to the study coordinator at 416-340-4800 x 4251 or mcrwe@uhn.ca (1).
Reference
- Avicanna Inc. Avicanna announces medical cannabis real world evidence study through mymedi.ca https://www.globenewswire.com/en/news-release/2024/09/23/2951266/0/en/Avicanna-Announces-Medical-Cannabis-Real-World-Evidence-Study-through-MyMedi-ca.html (accessed Sep 23, 2024).
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
